NVP-231

SIGMA/N9289 - ≥98% (HPLC)

Synonym: N-[2-(benzoylamino)-6-benzothiazolyl]-Tricyclo[3.3.1.13,7]decane-1-carboxamide; adamantane-1-carboxylic acid (2-benzoylamino-benzothiazol-6-yl)amide

CAS Number: 362003-83-6
Empirical Formula (Hill Notation): C₂₅H₂₅N₃O₂S
Molecular Weight: 431.55
MDL Number: MFCD01988824
Linear Formula: C₂₅H₂₅N₃O₂S
Product Type: Chemical

Catalog Number	PKG Qty.	Price


45-N9289-5MG	5 mg	$163.00 1/EA	Add To Favorites
45-N9289-25MG	25 mg	$687.00 1/EA	Add To Favorites

Properties
Descriptions
Safety Info.
Basic Data

assay	≥98% (HPLC)
color	white to off-white
form	powder
InChI	1S/C25H25N3O2S/c29-22(18-4-2-1-3-5-18)28-24-27-20-7-6-19(11-21(20)31-24)26-23(30)25-12-15-8-16(13-25)10-17(9-15)14-25/h1-7,11,15-17H,8-10,12-14H2,(H,26,30)(H,27,28,29)/t15-,16+,17-,25-
InChI key	MVSSJPGNLQPWSW-CIRRPZLZSA-N
originator	Novartis
Quality Level	100
SMILES string	O=C(Nc1nc2ccc(NC(=O)C34C[C@H]5C[C@H](C[C@H](C5)C3)C4)cc2s1)c6ccccc6
solubility	DMSO: >10 mg/mL
storage temp.	2-8°C

Biochem/physiol Actions:	Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation.
Biochem/physiol Actions:	Ceramide kinase presents an attractive target for drug development because of its involvement in cell growth and inflammation. CerK biology is still poorly understood thus discovery and availability of inhibitors will facilitate research at this area. NVP-231 is a newly discovered potent, specific and reversible CerK inhibitor that competitively inhibits binding of ceraminde to CerK.
Features and Benefits:	This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here .
Packaging:	5, 25 mg in glass bottle

RIDADR	NONH for all modes of transport
WGK Germany	nwg
Flash Point(F)	Not applicable
Flash Point(C)	Not applicable

Purity	≥98% (HPLC)
Storage Temp.	2-8°C
UNSPSC	12352200

To Order From a Quote